Clinical Trial

SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2023 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The entire treatment process is divided into two phases: Phase I SBRT combined with PD-1/CTLA-4 bispecific antibody (AK104) and Phase II AK104 single-agent maintenance therapy.
Trial Details
NCT Number NCT05732662
Lead Sponsor The First People's Hospital of Changzhou
Conditions Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment 25 participants
Start Date 2023-04
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-02-17